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of treatment. Patients treated with TUR-B followed by 
radiotherapy were significantly older compared to patients 
with cystectomy before radiotherapy and were less likely to 
receive chemotherapy. There was no significant difference 
for the length of the interval between first treatment and 
radiotherapy for the three groups. Despite of this, type of 
surgical procedure before radiotherapy did not show an 
impact on overall survival (p = 0.86). 
 
Conclusion: In our study we found equal survival of patients 
treated with (chemo)radiotherapy after TUR-B only compared 
to patients with cystectomy prior to radiotherapy. Younger 
age and more concomitant chemotherapy of the latter group 
was not able to prolong survival.  
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Purpose or Objective: In cancers of the head and neck 
(HNCa), lymph node (LN) status is a critical prognostic factor. 
Further, the presence of extracapsular extension (ECE) has 
been shown prospectively to be a criterion for the addition of 
chemotherapy to postoperative radiation therapy. Limited 
data exist regarding ECE in inguinal or pelvic LNs from 
primary penile cancer (PeCa). 
 
Material and Methods: We retrospectively analyzed 
outcomes of patients with PeCa and pathologically confirmed 
LN across four international tertiary referral centers. Clinical 
and demographic characteristics were compared of outcomes 
(local control and overall survival) by ECE status and between 
those who had received adjuvant RT or not. 
 
Results: Records of 93 patients were available. Median age at 
time of LND was 65.3 years (range 35.9–90.2 years). Median 
follow up was 9.4 months (IQR: 5.3-19.4). The median 
number of involved ILNs was 4 (range 1-12), and median PLNs 
positive was 2 (range 1-21). 72% of patients had ECE in the 
inguinal area and 49% had ECE in the pelvis. Infield failure 
occurred in 26/87 sites with ECE and 8/64 sites without ECE 
(p = 0.015). In the presence of ECE, patients receiving RT 
experienced infield failure in 17/50 cases and in 10/38 
patients not receiving RT (P=NS). Absent ECE, patients failed 
infield in 5/40 cases after RT and 3/24 cases without RT 
(p=NS). RT was not associated with improved OS (p=0.073) or 
recurrence (p=0.492) on multivariate analysis. Chemotherapy 
was significant on multivariate analysis for recurrence (p = 
0.009) but not survival (p=0.334). 
 
Conclusion: ECE is associated with increased likelihood of 
local recurrence in PeCa patients. Contrary to the experience 
in HNCa, adjuvant RT has no impact on local control. 
Prospective studies are needed to validate this unusual 
finding and further develop the timing and roles of RT and 
chemotherapy for PeCa patients with advanced disease. 
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Purpose or Objective: the aim of this study was the 
evaluation of local control (LC) and toxicity in 
oligometastatic patients with renal cell carcinoma (RCC) who 
had undergone stereotactic radiotherapy (SRT) with 
CyberKnife (Accuray, Sunnyvale, CA) or Vero™ (BrainLab) for 
cranial and extracranial metastases. 
 
Material and Methods: between January 2012 and September 
2015, 23 patients (30 lesions) with metastases of RCC were 
treated with SRT alone to the new site of disease (if limited 
disease) or to residual disease during the maximal response in 
systemic therapy. Disease control was evaluated with serial 
imaging. Toxicity was recorder according to the Common 
Toxicity Criteria version 4.0. 
 
Results: after a median follow-up of 10 months (range 0 - 36 
months) 20 patients were alive. Ten patients received SRT 
alone and 13 patients received that during the maximal 
response of systemic therapy. The median equivalent of the 
dose (EQD2) was 50.6 Gy delivered with a median of 2.7 
fractions (range 1-5) and the median biological equivalent 
dose (BED) was 51 Gy assuming α/β =10 for tumour. Six 
patients are lost in follow-up. Clinical and radiological 
response was thus evaluated in 17 patients and the their LC 
was 100% (57.1% of patients received SRT alone and the 
others patients are still undergoing systemic treatment. 
27.7% of patients had more than 12 months follow-up and the 
LC was again 100%. ). Progression of disease in the other sites 
was observed in all cases. No toxicity was observed. 
 
Conclusion: SRT is a feasible approach that offer an 
excellent LC with low toxicity profile in the treatment 
management of oligometastatic patients with RCC with or 
without the association of systemic therapy. Further 
investigation is warranted to identify the patients who would 
probably benefit from this approach. 
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